(reported by the Company)
No items found
Acuvax Ltd (ASX: ACU) is in the process of acquiring Biolife Science Ltd, which is developing a vaccine for breast and gastric cancers. On 22 March 2013, Acuvax shareholders voted overwhlemingly to approve the acquisition of Biolife and to raise $5m to fund Phase 2 trials of the vaccine.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):||ACU|
|Year of Commencement:||2001|
Suite 4, 16 Ord Street, WEST PERTH, WA, AUSTRALIA, 6005